ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 874

Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19)  in Giant-Cell Arteritis Lesions.  Potential Role of p40 in Promoting Th1 -Mediated Pathways

Georgina Espígol-Frigolé1, Ester Planas-Rigol1, Ester Lozano2, Marc Corbera-Bellalta2, Nekane Terrades-Garcia2, Sergio Prieto-González1, Ana García-Martínez3, Jose Hernández-Rodríguez2 and Maria C. Cid4, 1Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 2Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Emergeny Department, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 4Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cytokines and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  GCA has been considered a Th1-mediated disease. In recent years it has become apparent that Th17-mediated mechanisms may also play a role in GCA pathogenesis. Interleukin-12 is a heterodimeric cytokine (p35/p40) involved in Th1 functional differentiation of T lymphocytes. When combining with p19 subunit, p40 compose IL-23, a powerful pro-inflammatory cytokine that promotes Th17 response. P40, p35 and p19 are known to be expressed in GCA lesions but their distribution, association and functional roles have not been investigated. The aims of this study were 1) to investigate IL12p40, IL12p35 and IL23p19 subunit expression in GCA lesions and their combination to conform different cytokines 2) to investigate the effect of glucocorticoid treatment on subunit expression 3) to explore functional roles of p40 by culturing temporal artery sections with a neutralizing anti-human IL12/IL23p40 antibody.

Methods:  IL-12/IL23p40, IL12p35 and IL23p19 mRNA were measured by qRT-PCR in temporal arteries from 50 patients with biopsy-proven GCA and 20 patients with negative temporal artery biopsies, eventually diagnosed with other conditions. 36 patients were treatment naïve and 14 had received glucocorticoid treatment for 7 days (range 2-12) before the performance of temporal artery biopsy. Cytokine subunit distribution was assessed by immunofluorescence. Proximity ligation assay (PLA) was used to assess spatial relationship between subunits to conform different cytokines. Temporal arteries from 10 patients and 10 controls were cultured on 3D-matrix (Matrigel) and exposed to a neutralizing goat anti-human p40 antibody (R&D Systems) or dexamethasone (0.5 μg/mL) .Mann-Whitney test was used for statistical analysis.

Results: p40 and p19 mRNA concentrations were significantly higher in patients than in controls .No significant differences were found in constitutively expressed p35 mRNA levels between patients and controls. P40 and p19 mRNA expression was significantly decreased in treated GCA patients versus those treatment-naïve. Interestingly, immunofluorescence staining revealed intense p19 expression by inflammatory cells, independent from p40 expression. Although p40 expression was less abundant than other subunits, association between subunits to conform IL-23 could be confirmed by PLA in GCA lesions. Neutralization of IL-12/IL-23p40 tended to reduce IFNg mRNA production in cultured temporal arteries from GCA patients with no effect on IL-17, TNFa or IL-6. Dexamethasone significantly down-regulated IFNg, IL-17, TNFa and IL-6 in cultured arteries.

Conclusion: p40 and p19 mRNA expression are increased in active lesions from patients with GCA and decrease with glucocorticoid treatment. P19 subunit is much more expressed than p40 in GCA temporal arteries, indicating an independent role for p19 or its potential association with unidentified subunits. Neutralization of IL12/IL23p40 seems to mainly inhibit the Th1-mediated pathway by reducing IFNg levels. Supported by SAF 2014 57708-R , PIE13/00033 and FEDER.


Disclosure: G. Espígol-Frigolé, None; E. Planas-Rigol, None; E. Lozano, None; M. Corbera-Bellalta, None; N. Terrades-Garcia, None; S. Prieto-González, None; A. García-Martínez, None; J. Hernández-Rodríguez, None; M. C. Cid, None.

To cite this abstract in AMA style:

Espígol-Frigolé G, Planas-Rigol E, Lozano E, Corbera-Bellalta M, Terrades-Garcia N, Prieto-González S, García-Martínez A, Hernández-Rodríguez J, Cid MC. Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19)  in Giant-Cell Arteritis Lesions.  Potential Role of p40 in Promoting Th1 -Mediated Pathways [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/expression-and-function-of-il-1223-related-cytokine-subunits-p35-p40-and-p19-in-giant-cell-arteritis-lesions-potential-role-of-p40-in-promoting-th1-mediated-pathways/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-and-function-of-il-1223-related-cytokine-subunits-p35-p40-and-p19-in-giant-cell-arteritis-lesions-potential-role-of-p40-in-promoting-th1-mediated-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology